About the Authors
- Wahyu Wulaningsih
-
Affiliation King’s College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom
- Lars Holmberg
-
Affiliations King’s College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom, Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden, Regional Cancer Centre, Uppsala, Sweden
- Hans Garmo
-
Affiliations King’s College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom, Regional Cancer Centre, Uppsala, Sweden
- Björn Zethelius
-
Affiliations Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden, Medical Products Agency/Epidemiology, Uppsala, Sweden
- Annette Wigertz
-
Affiliation Regional Cancer Centre, Uppsala, Sweden
- Paul Carroll
-
Affiliation Department of Endocrinology, Guy’s & St Thomas’ NHS Foundation Trust, St. Thomas’ Hospital, London, United Kingdom
- Mats Lambe
-
Affiliations Regional Cancer Centre, Uppsala, Sweden, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Niklas Hammar
-
Affiliations Department of Epidemiology, Insitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, AstraZeneca Sverige, Södertalje, Sweden
- Göran Walldius
-
Affiliation Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- Ingmar Jungner
-
Affiliation Department of Medicine, Clinical Epidemiological Unit, Karolinska Institutet and CALAB Research, Stockholm, Sweden
- Mieke Van Hemelrijck
-
* E-mail: mieke.vanhemelrijck@kcl.ac.uk
Affiliation King’s College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom
Competing Interests
Björn Zethelius is employed by the Medical Products Agency (MPA), Uppsala, Sweden and the views of the present study are his own and not necessarily any official views of the MPA. Niklas Hammar is employed by the AstraZeneca Sverige, Södertalje, Sweden and the views of the present study are his own and not necessarily any official views of the AstraZeneca Sverige. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Interpreted analysis results: WW LH HG BZ PC MVH. Edited and reviewed manuscript: WW LH HG BZ AW PC ML NH GW IJ MVH. Conceived and designed the experiments: WW HG MVH. Performed the experiments: WW. Analyzed the data: WW HG. Contributed reagents/materials/analysis tools: LH AW ML NH GW IJ MVH. Wrote the paper: WW.